Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xencor

10.65
+0.05000.47%
Post-market: 10.650.00000.00%18:58 EDT
Volume:811.15K
Turnover:8.51M
Market Cap:750.42M
PE:-2.98
High:10.81
Open:10.73
Low:10.20
Close:10.60
Loading ...

Xencor Raised to Overweight From Neutral by Piper Sandler

Dow Jones
·
02 Dec 2024

Xencor to Participate at Upcoming Investor Conferences

Business Wire
·
27 Nov 2024

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

Zacks
·
14 Nov 2024

PRIMECAP Management Bolsters Stake in Xencor Inc

GuruFocus
·
13 Nov 2024

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Simply Wall St.
·
12 Nov 2024

Barclays Sticks to Its Sell Rating for Xencor (XNCR)

TIPRANKS
·
08 Nov 2024

Xencor Is Maintained at Overweight by JP Morgan

Dow Jones
·
08 Nov 2024

Xencor (NASDAQ:XNCR) shareholders are up 7.9% this past week, but still in the red over the last three years

Simply Wall St.
·
07 Nov 2024

Xencor Inc reports results for the quarter ended in January 1 - Earnings Summary

Reuters
·
07 Nov 2024

Xencor’s Strategic Advancements and Promising Pipeline Drive Buy Rating

TIPRANKS
·
07 Nov 2024

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
07 Nov 2024

Xencor Q3 EPS $(0.71) Beats $(0.96) Estimate, Sales $10.71M Miss $13.29M Estimate

Benzinga
·
07 Nov 2024

Xencor reports Q3 EPS (71c), consensus (98c)

TIPRANKS
·
07 Nov 2024

Xencor sees 2024 year end cash $690M-$710M

TIPRANKS
·
07 Nov 2024

Xencor: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

BRIEF-Xencor Q3 Operating Expenses USD 72.993 Million

Reuters
·
07 Nov 2024

Xencor Reports Third Quarter 2024 Financial Results

Business Wire
·
07 Nov 2024

Xencor’s Promising Advancements and Strategic Developments Justify Buy Rating

TIPRANKS
·
06 Nov 2024

BRIEF-Xencor Doses First Subject In Phase 1/2 Study Of Xmab®942 In Development For Patients With Inflammatory Bowel Disease

Reuters
·
04 Nov 2024

Xencor Doses First Subject in Phase 1/2 Study of Xmab®942 in Development for Patients With Inflammatory Bowel Disease

THOMSON REUTERS
·
04 Nov 2024